NCT07402356 · RECRUITING

VR Pupillometry in Cognitive Impairment

This study is testing whether a VR headset that tracks pupil responses can detect early signs of cognitive decline. Researchers will compare pupil behavior during memory and attention tasks across four groups: Alzheimer's disease, mild cognitive impairment, depression with cognitive symptoms, and healthy adults. Participants are followed over six months. This is an observational study, not a drug trial, so it is testing a diagnostic tool, not a treatment.

You may qualify if

  • Written informed consent.
  • Age 18-80 years.
  • Ability to read and understand German.
  • For patient cohorts: suspected or confirmed diagnosis of AD/MCI/depressive disorder with cognitive impairment according to clinical assessment and routine documentation.

You're excluded if

  • Acute suicidality (e.g. BDI suicidality item > 1).
  • Change of psychotropic medication within the last 4 weeks.
  • Lifetime psychotic disorder (ICD-10 F20-29).
  • Lack of capacity to consent.
  • Lifetime bipolar disorder (ICD-10 F31).
  • Acute substance abuse or harmful use of alcohol or other psychoactive substances.
  • Parkinson's syndrome (ICD-10 G20).
  • Multiple sclerosis (ICD-10 G35).
  • Stroke within the last 12 months.

The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.

Eligibility criteria as of 2026-02-17

View full record on ClinicalTrials.gov

All APOE4 clinical trials